ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IMMUCELL CORP /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.51−0.24 (-2.23%)
Close on Oct 19, 2026
- Market cap
- $96.58M
- P/E (TTM)
- 131.4
- Dividend yield
- –
IMMUCELL CORP /DE/ revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment, Scours [Member] | $7.11M | $10.31M | $7.58M | $5.44M | $6.40M | $8.03M | $7.71M | $5.95M | – | – | – | – | 99.0% | +11.1% |
| Corporate Segment, Mastitis [Member] | $75.34K | $49.52K | $49.83K | $61.50K | $46.36K | $38.69K | $38.93K | $60.23K | – | – | – | – | 1.0% | +62.5% |
| Scours [Member] | – | – | – | – | $6.40M | $8.03M | $7.71M | $5.95M | $5.43M | $7.22M | $5.04M | $5.36M | – | – |
| Mastitis [Member] | – | – | – | – | $46.36K | $38.69K | $38.93K | $60.23K | $42.82K | $36.94K | $55.58K | $36.44K | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment, Mastitis [Member] | $2.07M | -$157.78K | -$821.48K | -$638.44K | -$762.69K | -$698.40K | -$807.91K | -$837.35K | – | – | – | – | -370.9% |
| Corporate Segment, Scours [Member] | $1.17M | $3.32M | $1.92M | $1.42M | $2.08M | $2.47M | $2.04M | $827.67K | – | – | – | – | -43.8% |
| Other [Member] | – | – | – | – | -$748.52K | -$657.29K | -$612.99K | -$565.21K | -$638.01K | -$562.05K | -$558.91K | -$551.10K | – |
| Scours [Member] | – | – | – | – | $2.08M | $2.47M | $2.04M | $827.67K | $310.11K | $1.60M | $673.86K | $623.22K | – |
| Mastitis [Member] | – | – | – | – | -$762.69K | -$698.40K | -$807.91K | -$837.35K | -$1.06M | -$1.34M | -$1.12M | -$1.26M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Defense product line [Member] | – | – | – | – | $6.40M | $8.03M | $7.71M | $5.95M | $5.43M | $7.22M | $5.04M | $5.36M | – | – |
| Other animal health [Member] | – | – | – | – | $46.36K | $38.69K | $38.93K | $60.23K | $42.82K | $36.94K | $55.58K | $36.44K | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other [Member] | – | – | – | – | $1.57M | $892.28K | $1.31M | $795.17K | $580.75K | $916.94K | $320.27K | $473.24K | – | – |
| United States | – | – | – | – | $4.87M | $7.17M | $6.44M | $5.22M | $4.89M | $6.34M | $4.78M | $4.92M | – | – |
From the segment and revenue-disaggregation notes of Immucell's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.